This is an exciting opportunity to become a key member of the Finance organization supporting a dynamic, fast-moving biotechnology company. Under the leadership of the Corporate Controller, this role will manage the financial closing process all aspects of the SEC external reporting including the preparation and submission of all SEC filings and the design and documentation of internal controls. S/he will also assist with the implementation of technical accounting pronouncements and partner on the financial management of the company.
Lead the company's external reporting process, preparation and filing of SEC filings (10Qs, 10Ks), providing for the timely and accurate filing in compliance with authoritative accounting guidance and regulations, including: the coordination, lead the financial closing process and review and design of work papers supporting the Company's quarterly and annual financial statements filed with the SEC; management of the company's internal controls over financial reporting framework; and researching, documenting and communicating new GAAP, SEC and other disclosure issues.
Ensure that the company's accounting procedures and reported results confirm to generally accepted accounting principles (GAAP).
Providing technical accounting support to the organization as required, including primary responsibility for managing all aspects of technical accounting analysis and financial evaluations of potential licensing arrangements, investments, acquisitions, and other business opportunities.
Support and adhere to strong internal control policies and procedures, including identifying areas for improvement that support efficient and timely SEC filing
Manage the quarterly audits and provide auditors with the necessary documentation
Collaborate with other finance and business stakeholders to support department initiatives, including implementations of accounting-related systems/applications and process improvements
Maintain SOX schedules and internal control documentation and manage the SOX 404 audits, including the preparation of PBCs (prepared by client schedules) to support our SEC filings
Establish and maintain strong business partnerships with key counterparts including, FP&A, Procurement, and functional business owners
Assist in the development of departmental initiatives and goals and the strategies to achieve those initiatives and goals
Partnering with outside advisors, vendors, consultants and legal to meet tax requirements and optimizing legal and capital structures.
Bachelor's degree in Accounting and CPA required, with strong knowledge of GAAP, SEC reporting requirements and relevant accounting and financial concepts; Big 4 accounting audit firm experience preferred
A minimum of 7-10 years of public accounting and/or industry experience in a public company (biotechnology, pharmaceutical, medical device preferred)
Ability to apply judgment and is solutions oriented with strong analytical and problem-solving skills; ability to combine attention to detail with an understanding of broader strategic context.
Self-directed, accomplishment driven individual with strong sense of passion and urgency
Comfortable with ambiguity; ability to work well in a collaborative, fast-paced, dynamic environment.
Strong project management skill set and experience; ability to manage multiple initiatives concurrently.
Experience working cross-functionally across an organization with demonstrated ability to interact with and build productive working relationships across all organizational levels.
Strong interpersonal skills with ability to influence and motivate others, negotiate during situational conflict and establish best path forward in the fact of competing objectives.
Possesses "can do" attitude and willingness to roll-up sleeves.
Experience with Oracle Fusion a plus.
Level will be determined based on experience
Corbus is a close-knit team of almost 150 employees who are high-achievers, innovative, creative and, above all else, passionate about what we do. We hire for personality as well as for skill.
You must thrive in an entrepreneurial and autonomous environment where you will succeed based on your contribution and work ethic, not on your title or rank. At Corbus we take pride in our "family" atmosphere where each person's contribution is vital to our success.
As a Corbus employee, you are empowered to think creatively and be proactive in your approach. There is no place for politics or red tape here. Positive, team-oriented people work at Corbus and are rewarded with fun perks like weekly food deliveries to our kitchen, a monthly in-house massage therapist, company-paid classes with Title Boxing, and organized company activities and outings. Additionally, Corbus offers an attractive, comprehensive benefits package.
Corbus Pharmaceuticals Holdings, Inc. (NASDQ: CRBP) is a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat inflammatory and fibrotic diseases by leveraging its industry leading pipeline of endocannabinoid system-targeting drug candidates.
The Company's lead product candidate, Lenabasum, is a novel, synthetic, oral, selective cannabinoid receptor type 2 (CB2) agonist designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus.
Corbus licensed the exclusive worldwide rights to develop, manufacture and market drug candidates from more than 600 novel compounds targeting the endocannabinoid system from Jenrin Discovery LLC. The pipeline includes CRB-4001, a 2nd generation, peripherally-restricted, selective cannabinoid receptor type 1 (CB1) inverse agonist specifically designed to eliminate blood-brain barrier penetration and brain CB1 receptor occupancy that mediate the neuropsychiatric issues associated with first-generation CB1 inverse agonists.
Potential indications for CRB-4001 include NASH, primary biliary cholangitis, idiopathic pulmonary fibrosis, radiation-induced pulmonary fibrosis, myocardial fibrosis after myocardial infarction and acute interstitial nephritis, among others. CRB-4001 is scheduled to enter a Phase 1 study in 2019 followed a National Institutes of Health (NIH)-funded first-in-patient Phase 2 study.
Corbus Pharmaceuticals Holdings, Inc. is an equal opportunity employer
Corbus Pharmaceuticals Holdings, Inc.